Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ACT-541468 on Rosuvastatin PK
NCT03339752Phase 1Completed
- Sponsor
- Idorsia
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daridorexant in Insomnia, sponsored by Idorsia. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Plasma Concentration at Day 8 and 3 more. Started Oct 2017; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03339752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339752.